A pancreas tumor derived organoid study: from drug screen to precision medicine

Pancreatic ductal adenocarcinoma (PDAC) one of the deadliest malignant tumor. Despite considerable progress in pancreatic cancer treatment in the past 10 years, PDAC mortality has shown no appreciable change, and systemic therapies for PDAC generally lack efficacy. Thus, developing biomarkers for tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Jia, Yang, Man, Atteh, Lawrence, Liu, Pinyan, Mao, Yongcui, Meng, Wenbo, Li, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314636/
https://www.ncbi.nlm.nih.gov/pubmed/34315500
http://dx.doi.org/10.1186/s12935-021-02044-1
Descripción
Sumario:Pancreatic ductal adenocarcinoma (PDAC) one of the deadliest malignant tumor. Despite considerable progress in pancreatic cancer treatment in the past 10 years, PDAC mortality has shown no appreciable change, and systemic therapies for PDAC generally lack efficacy. Thus, developing biomarkers for treatment guidance is urgently required. This review focuses on pancreatic tumor organoids (PTOs), which can mimic the characteristics of the original tumor in vitro. As a powerful tool with several applications, PTOs represent a new strategy for targeted therapy in pancreatic cancer and contribute to the advancement of the field of personalized medicine.

Ejemplares similares